Firefly Neuroscience (NASDAQ:AIFF) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Firefly Neuroscience (NASDAQ:AIFF) from a hold rating to a sell rating in a research report released on Saturday.

Separately, Weiss Ratings raised Firefly Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 19th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Firefly Neuroscience has an average rating of “Sell”.

Firefly Neuroscience Stock Down 6.0%

Shares of NASDAQ AIFF opened at $1.09 on Friday. The company has a market capitalization of $17.10 million, a PE ratio of -1.85 and a beta of 0.57. Firefly Neuroscience has a twelve month low of $0.62 and a twelve month high of $3.63. The firm has a fifty day simple moving average of $1.25 and a 200 day simple moving average of $1.46.

Firefly Neuroscience (NASDAQ:AIFF) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.10) EPS for the quarter. Firefly Neuroscience had a negative net margin of 506.23% and a negative return on equity of 90.17%. The firm had revenue of $0.51 million for the quarter.

Institutional Investors Weigh In On Firefly Neuroscience

Several hedge funds and other institutional investors have recently modified their holdings of AIFF. Vanguard Group Inc. raised its position in shares of Firefly Neuroscience by 393.3% during the third quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after purchasing an additional 401,085 shares during the period. Geode Capital Management LLC grew its position in Firefly Neuroscience by 92.9% in the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after purchasing an additional 58,067 shares during the period. Jane Street Group LLC acquired a new stake in Firefly Neuroscience in the 4th quarter valued at $53,000. Finally, BlackRock Inc. acquired a new stake in Firefly Neuroscience in the 2nd quarter valued at $226,000. Institutional investors own 4.96% of the company’s stock.

About Firefly Neuroscience

Firefly Neuroscience is a clinical?stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real?world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone?based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.